Polycystic ovary syndrome – Phenotypes and diagnosis

References

• Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–11.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008;10:e3.
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007;67:735–42.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Christakou C, Palioura E, et al. Does polycystic ovary syndrome start in childhood? Pediatr Endocrinol Rev 2008;5:904–11.
   PubMedGoogle Scholar
• Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications, 1992: 377–84.
   Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome (PCOS): Hum Reprod 2004;19:41–7.
   Google Scholar
• Azziz R CE, Dewailly D, Diamanti-Kandarakis E, et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88.
   PubMed Web of Science ®Google Scholar
• Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251–7.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis Ε, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des 2012;18:270–82.
   PubMed Web of Science ®Google Scholar
• Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones 2014;13:1–9.
   Google Scholar
• Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008;69:634–41.
   PubMed Web of Science ®Google Scholar
• Jonard S, Robert Y, Cortet-Rudelli C, et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598–603.
   PubMed Web of Science ®Google Scholar
• Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003, 9:505–14.
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Knauff EA, Valkenburg O, et al. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Brit J Obstet Gynecol 2006;113:1210–17.
   Google Scholar
• Rosenfield R. Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787–96.
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Bairey Merz CN, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Womens Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276–84.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27: 3067–73.
   PubMed Web of Science ®Google Scholar
• Rosner W, Auchus RJ, Azziz R, et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92:405–413.
   PubMed Web of Science ®Google Scholar
• Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15:477–88.
   PubMed Web of Science ®Google Scholar
• Dilbaz B, Ozkaya E, Cinar M, et al. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 2011;39:272–7.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–9.
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE–PCOS) Society. J Clin Endocrinol Metab 2010;95:2038–49.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Palioura E, Kandarakis SA, et al. The impact of endocrine disruptors on endocrine targets. Horm Metab Res 2010;42:543–52.
   PubMed Web of Science ®Google Scholar
• Palioura E, Diamanti-Kandarakis E. Industrial endocrine disruptors and polycystic ovary syndrome. J Endocrinol Invest 2013;36(11):1105–11.
   Google Scholar
• Diamanti-Kandarakis E, Piouka A, Livadas S, et al. Anti-müllerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 2009;160:847.
   PubMed Web of Science ®Google Scholar
• Merhi Z. Advanced glycation end products and their relevance in female reproduction Hum Reprod 2014;29: 135–45.
   PubMed Web of Science ®Google Scholar